中科院成都信息技术股份有限公司（以下简称"公司"）第四届董 事会第二十四次会议于 2025 年 10 月 17 日以电子邮件方式发出会议通 知，本次会议于 2025 年 10 月 29 日以联签方式召开。会议应参与表决 董事为 9 名，实际参与表决董事 9 名。会议由公司董事长史志明主持， 公司董事会秘书、财务负责人列席了会议。本次会议的召集、召开和表 决程序符合有关法律、行政法规、部门规章、规范性文件及公司章程的 规定。 证券代码：300678 证券简称：中科信息 公告编号：2025-077 中科院成都信息技术股份有限公司 第四届董事会第二十四次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、会议召开情况 二、会议审议情况 与会董事对《通知》所列之议案进行了审议并通过了如下事项： （一）审议通过《关于 2025 年第三季度报告的议案》 经审议，董事会认为公司《2025 年第三季度报告》的编制程序符合 法律法规和中国证监会的有关规定，报告内容真实、准确、完整地反映 了公司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 （二）审议通过 ...

Core Insights - The Chinese optogenetics industry has made significant progress, transitioning from a technology follower to a leader, with a market size projected at approximately 5.276 billion yuan in 2024, reflecting a year-on-year growth of 9.10% [1][11] - Domestic research teams have achieved breakthroughs in the development of photosensitive proteins, gene delivery systems, and optical equipment, enhancing the efficiency and precision of optogenetics applications [1][11] - Despite advancements, existing optogenetic tools still face limitations, such as large control modules, poor tissue penetration, off-target effects, and optical toxicity, necessitating ongoing optimization [1][11] Industry Overview - Optogenetics combines optical and genetic techniques to control cell activity by expressing light-sensitive ion channels, pumps, or enzymes in target cells [2] - The basic principle involves inserting opsin genes into target neurons, allowing them to respond to specific wavelengths of light, thereby regulating ionic flow and neuronal activity [2] Industry Development History - The Chinese optogenetics industry has evolved through three main phases: early exploration and technology foundation (2004-2010), technological breakthroughs and clinical application exploration (2011-2020), and accelerated clinical translation and industrialization (2021-present) [4] - Key milestones include the first successful retinal treatment in 2016 and the development of the REDMAP system in 2023 [4] Industry Value Chain - The upstream of the optogenetics industry includes photosensitive proteins, gene delivery systems, raw materials, hardware systems, and auxiliary technologies [6] - The midstream focuses on optogenetics technology services, product research and development, while the downstream applications span neuroscience, cross-disciplinary fields, ophthalmology, neurology, cardiac diseases, and metabolic disorders [6] Market Size - The optogenetics market in China is expected to reach approximately 5.276 billion yuan in 2024, with a growth rate of 9.10% year-on-year [11] - Technological advancements, such as the REDMAP light switch developed by East China Normal University, have contributed to this market expansion [11] Industry Trends 1. **Innovative Technological Breakthroughs**: The industry is driven by technological innovation, facilitating rapid translation from laboratory to clinical applications, exemplified by the REDMAP light switch and ZM-02 gene therapy [14][16] 2. **Policy Support and Capital Acceleration**: National policies supporting innovative drugs and dynamic adjustments to medical insurance directories are stimulating the commercialization of optogenetic therapies [16] 3. **Cross-Disciplinary Applications**: Optogenetics is expanding beyond neuroscience into fields like tumor treatment, metabolic diseases, and mental health, fostering multi-disciplinary integration [17]

Core Viewpoint - Zhongke Information announced the resignation of independent directors Li Zhishu and Cao Dejun, who have served since August 29, 2019, marking the end of their six-year term [2] Group 1 - The board of directors received written resignation reports from independent directors Li Zhishu and Cao Dejun [2] - Both directors applied to resign from their positions on the fourth board of directors and related committees [2] - After their resignation, they will no longer hold any positions within the company [2]

中科院成都信息技术股份有限公司 关于独立董事任期届满的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 中科院成都信息技术股份有限公司(以下简称"公司")董事会于近 日收到公司独立董事李志蜀先生、曹德骏先生的书面辞职报告。李志蜀 先生、曹德骏先生自 2019 年 8 月 29 日以来连续担任公司独立董事已届 满六年，根据《上市公司独立董事管理办法》关于上市公司独立董事连 续任职年限的有关规定，李志蜀先生、曹德骏先生申请辞去公司第四届 董事会独立董事职务及董事会各专门委员会相关职务，辞职后不再担任 公司任何职务。 证券代码：300678 证券简称：中科信息 公告编号：2025-076 2 / 2 鉴于李志蜀先生、曹德骏先生的离任将导致公司第四届董事会中独 立董事占董事会成员比例低于三分之一，根据《上市公司独立董事管理 办法》和《公司章程》等有关规定，李志蜀先生、曹德骏先生的辞职将 在公司股东会选举产生新任独立董事之日生效。在新任独立董事就任前， 李志蜀先生、曹德骏先生仍将继续履行独立董事职责及其在董事会各专 门委员会中的相关职责。公司将依照法定程序尽快完成新 ...

Core Insights - The company has not developed brain-computer interface technology and equipment but is utilizing it as an auxiliary tool for its smart medical business [1] - The company aims to develop a closed-loop brain-machine interface (BMI) system based on optogenetic control to meet the needs of smart anesthesia and smart rehabilitation applications [1] Business Development - In 2022, the company established the "Brain Cognition and Smart Medical Innovation Application Laboratory" approved by Chengdu, focusing on key technologies in artificial intelligence and medical engineering [1] - The laboratory is building platforms for technology research and development, business development, and mobile application development, with plans to upgrade products in smart anesthesia assistance, IoT medical devices, integrated regional smart medical and health platforms, and rehabilitation products [1] Strategic Partnerships - The company is collaborating with the Suzhou Institute of Nano-Tech and Nano-Bionics of the Chinese Academy of Sciences to establish a brain-like intelligence and smart medical industry-university-research center [1] - This partnership aims to conduct research on key technologies and innovative applications, targeting clinical auxiliary diagnosis and treatment, clinical scientific research, and regional health and wellness applications [1] Financial Performance - In the first half of 2025, the company achieved revenue of 142 million yuan, a year-on-year decrease of 6.61% [1] - The net profit attributable to the parent company was 4 million yuan, down 24.48% year-on-year [1]

Core Viewpoint - The company is not engaged in the research and development of brain-computer interface (BCI) technology and equipment, but is utilizing BCI technology as an auxiliary tool for its smart medical business development [1] Group 1: Business Development - The company is developing a closed-loop brain-computer interface (BMI) system based on optogenetic regulation to meet the needs of smart anesthesia and smart rehabilitation applications [1] - In 2022, the company established the "Brain Cognition and Smart Medical Innovation Application Laboratory" approved by Chengdu, focusing on key technologies in artificial intelligence and medical engineering [1] Group 2: Strategic Partnerships - The company is collaborating with the Suzhou Institute of Nano-Tech and Nano-Bionics of the Chinese Academy of Sciences to build a brain-like intelligence and smart medical industry-university-research center [1] - The partnership aims to conduct research on key technologies and innovative applications, targeting clinical auxiliary diagnosis and treatment, clinical scientific research, and regional medical and health integration [1] Group 3: Product Development - The company is developing a series of products including upgraded systems for intelligent anesthesia assistance, IoT medical devices, integrated platforms for regional smart medical and health services, and upgraded rehabilitation products [1] - The focus is on creating high-end intelligent medical and rehabilitation devices, high-end wearable devices, and clinical research and auxiliary diagnosis systems and equipment as part of domestic innovation [1]

Core Insights - The company is actively developing AI intelligent agent businesses, particularly in the fields of smart education and software development [1] Group 1: Smart Education - The company, in collaboration with Chengdu Zhixue Education, has successfully implemented the Deepseek+ intelligent agent "Comprehensive Resource Management Platform" aimed at the smart education sector [1] - This platform utilizes a privatized deployment of the Deepseek AI model, tailored to the actual teaching needs of schools, enhancing training environments and optimizing experimental conditions [1] - The goal is to continuously improve teaching support capabilities and comprehensively enhance educational conditions [1] Group 2: Software Development - The company is developing two intelligent agents for the software development sector [1] - One agent is a high-performance Text2SQL data analysis tool that assists developers by converting natural language requests into SQL statements, improving development efficiency and database comprehension [1] - The second agent focuses on generating software test cases by analyzing various formats of requirement documents, extracting key testing points, and producing comprehensive test cases with human validation [1]

Group 1 - The core point of the article highlights the recent decline in the stock price of Zhongke Information, which has dropped 4.3% to 33.63 CNY per share, with a total market capitalization of 9.967 billion CNY and a cumulative decline of 6.3% over three days [1] - Zhongke Information, established on June 26, 2001, and listed on July 28, 2017, specializes in intelligent recognition and analysis technology, providing information solutions, with revenue composition of 50.83% from technical services and development, 47.01% from information solutions, and 2.16% from other sources [1] - The major shareholder, GF Fund, increased its holdings in GF CSI 1000 ETF by 19.85 thousand shares, bringing the total to 91.33 thousand shares, representing 0.31% of the circulating shares, with a floating loss of approximately 137.92 thousand CNY today and a total floating loss of 206.42 thousand CNY over the three-day decline [2] Group 2 - The fund manager of GF CSI 1000 ETF, Luo Guoqing, has a tenure of 10 years and 5 days, with the fund's total asset size at 67.565 billion CNY, achieving a best return of 82.85% and a worst return of -48.08% during his tenure [3]

Core Viewpoint - The company Zhongke Information (300678) is focusing on specific sectors such as smart governance, intelligent manufacturing, smart cities, and smart healthcare, rather than expanding into areas like intelligent driving and humanoid robots [2]. Group 1: Company Performance - As of October 10, 2025, Zhongke Information's stock closed at 35.39 yuan, down 1.39%, with a turnover rate of 2.54% and a trading volume of 74,000 shares, resulting in a transaction amount of 265 million yuan [1]. - On the same day, the net outflow of main funds was 6.8041 million yuan, while the net inflow of speculative funds was 6.972 million yuan, and retail investors experienced a net outflow of 167,900 yuan [2]. Group 2: Business Focus - The company has developed intelligent anesthesia robots for the medical field and intelligent loading and paving robots for the construction sector, showcasing its commitment to specific applications rather than broader fields like intelligent driving [2].

Core Viewpoint - The company focuses on four business sectors: smart government affairs, intelligent manufacturing, smart cities, and smart healthcare, emphasizing technology research and market development [1] Business Segments - The company has independently developed intelligent anesthesia robots for the healthcare sector and intelligent loading and paving robots for the construction sector [1] - The company's high-speed machine vision and intelligent analysis technology have broad applicability across multiple industry fields [1] Current Business Focus - Currently, the company does not have any business related to intelligent driving or humanoid robots [1]